1
|
González-Stegmaier R, Cereceda K, Briones JL, Beltran-Pávez C, Oyarzún-Arrau A, Riquelme-Barrios S, Selman C, Yarad F, Mahave M, Caglevic C, Morales R, Aguirre A, Valiente-Echeverría F, Soto-Rifo R, Marsiglia H, Gazitua R, Villarroel-Espindola F. Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population. J Immunol Res 2021; 2021:6680337. [PMID: 33644235 PMCID: PMC7901042 DOI: 10.1155/2021/6680337] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 01/03/2021] [Accepted: 01/24/2021] [Indexed: 01/08/2023] Open
Abstract
COVID-19 is a pandemic caused by SARS-CoV-2. In Chile, half a million people have been infected and more than 16,000 have died from COVID-19. As part of the clinical trial NCT04384588, we quantified IgG against S1-RBD of SARS-CoV-2 (anti-RBD) in recovered people in Santiago and evaluated their suitability as COVID-19 convalescent plasma donors. ELISA and a luminescent SARS-CoV-2 pseudotype were used for IgG and neutralizing antibody quantification. 72.9% of the convalescent population (468 of 639) showed seroconversion (5-55 μg/mL anti-RBD IgG) and were suitable candidates for plasma donation. Analysis by gender, age, and days after symptom offset did not show significant differences. Neutralizing activity correlated with an increased concentration of anti-RBD IgG (p < 0.0001) and showed a high variability between donors. We confirmed that the majority of the Chilean patients have developed anti-SARS-CoV-2 antibodies. The quantification of anti-RBD IgG in convalescent plasma donors is necessary to increase the detection of neutralizing antibodies.
Collapse
Affiliation(s)
- R. González-Stegmaier
- Translational Medicine Laboratory, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - K. Cereceda
- Translational Medicine Laboratory, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - J. L. Briones
- Haematology Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - C. Beltran-Pávez
- Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Chile
- HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile, Chile
| | - A. Oyarzún-Arrau
- Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Chile
- HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile, Chile
| | - S. Riquelme-Barrios
- Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Chile
- HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile, Chile
| | - C. Selman
- Diagnostic Units, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
- Biobank, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - F. Yarad
- Diagnostic Units, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - M. Mahave
- Medical Oncology Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - C. Caglevic
- Cancer Research Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - R. Morales
- Internal Medicine Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - A. Aguirre
- Translational Medicine Laboratory, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - F. Valiente-Echeverría
- Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Chile
- HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile, Chile
| | - R. Soto-Rifo
- Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Chile
- HIV/AIDS Work Group, Faculty of Medicine, Universidad de Chile, Chile
| | - H. Marsiglia
- Radiotherapy Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - R. Gazitua
- Haematology Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | - F. Villarroel-Espindola
- Translational Medicine Laboratory, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
- Cancer Research Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| |
Collapse
|